Home

ASTN Current Trials



ESCAPE NA-1: Extension of Stroke Care by Added neuroProtection to Endovascular treatment

E-mail Print PDF

Lead PI: Professor Michael D Hill and Dr Mayank Goyal

Status: Recruiting

No. of Patients Currently Recruited: 143                                No. of Patients Required: 1120

ESCAPE-NA1 is examining the rapid addition of single dose NA-1 to the treatment of acute ischemic stroke patients with large vessel occlusion undergoing endovascular thrombectomy.  Patients are randomized 1:1 to study drug (active drug or saline placebo) and then followed for 90 days.  The primary outcome is disability measured on the modified Rankin Scale at 90 days.  Up to 1120 patients will be recruited from centres in Canada, US, Europe/UK, South Korea and Australia.

Trial URL:

www.escapena1.ca

https://clinicaltrials.gov/ct2/show/NCT02930018?cond=escape-na1&rank=1

NCT02930018

Last Updated ( Tuesday, 23 January 2018 13:17 )
 

TEXAIS: A Multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke

E-mail Print PDF

Lead PI: Professor Chris Bladin

Status: Site Selection

No. of Patients Currently Recruited: 0                               No. of Patients Required: 528

Phase 2, multicentre, prospective, randomised, open label, blinded end-point (PROBE) trial with pre-planned adaptive sample size re-estimation. 10 sites anticipated to randomise 528 (1:1 ratio) patients by 2019. Primary Hypothesis: Treatment with short acting Exenatide (Byetta) in patients with acute ischaemic stroke will improve neurological outcome as measured by >8 point improvement in NIHSS stroke disability score (or NIHSS 0-1) at 7 days.

Trial URL:

https://clinicaltrials.gov/ct2/show/NCT03287076

Last Updated ( Wednesday, 10 January 2018 13:00 )
 

TASTE: Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial

E-mail Print PDF

Lead PI: Professor Mark Parsons

Status: Recruiting

No. of Patients Currently Recruited: 197                                No. of Patients Required: 400

Multicentre, prospective, randomised open-label blinded endpoint (PROBE) phase III study including acute stroke patients with hemispheric ischaemia who have penumbra on perfusion CT (CTP) or MRI within 4.5 hours of stroke onset. The primary objective of this study is to test the hypothesis that patients with acute hemispheric ischaemic stroke who have a penumbra on perfusion CT or MRI within 4.5hrs of symptom onset will have less disability at 3 months when treated with IV TNK compared to IV tPA.

Trial URL:

http://clinicaltrials.gov.show/NCT01472926 
Last Updated ( Wednesday, 10 January 2018 13:01 )
 

INSPIRE: INternational Stroke Perfusion Imaging Registry

E-mail Print PDF

INSPIRE: INternational Stroke Perfusion Imaging REgistry

Lead PI:  John Hunter Hospital

Status: Recruiting

No. of Patients Currently Recruited: 1500                       No. of Patients Required: 2000

INSPIRE is an international web-based database collecting imaging and clinical stroke data to measure implementation of advanced CT image in stroke, So far, INSPIRE has recruited around 1500 patients from sitesacross Australi, China Canada and India. The fist stage of data analysis has been completed, leading to 4 research papers (3 ongoing and 1 published).

Trial URL:

 https://taste.newcastle.edu.au/key=inspire

 http://onlinelibrary.wiley.com/doi/10.1002/ana.24714/abstract

Last Updated ( Tuesday, 23 January 2018 13:24 )
 

CHARM: Cirara in large Hemispheric infarction Analysing mRS and Mortality

E-mail Print PDF
Lead PI: Dr Bruce Campbell

Status: ASTN endorsed

No. of Patients Currently Recruited: 0                                No. of Patients Required: tbc

Edema in larger hemispheric infarction can cause neurological deterioration and death. Intravenous glyburide acts on SUR-1 receptors to reduce edema after ischemic stroke. The hypothesis of the CHARM phase 3 randomised trial is that intravenous glyburide will improve the functional outcome after large hemispheric stroke compared to placebo.
Last Updated ( Thursday, 07 July 2016 14:07 )
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  Next 
  •  End 
  • »
Page 1 of 3

Members Login


ASTN Latest news

Top Views